Methods and compositions for inhibition of egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors

A method of treating a patient suffering from a non-small cell lung cancer (NSCLC) expressing the ELM4-ALK fusion gene, comprising administering to a patient in need of such treatment a flexible and active regimen for combining a ALK Inhibitor and passive administration of a monoclonal anti-EGF antibody, wherein in the ALK Inhibitors is administered according to a continuous regimen in a therapeutically effective daily and the passive immunization is co-administered according to a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly.

A method of treating a patient suffering from a non-small cell lung cancer (NSCLC) driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR) expressing the ELM4-ALK fusion gene, wherein:

• the patient has a tumor expressing mutated forms of the EGFR, comprising administering to a patient in need of such treatment a flexible and active regimen for combining a ALK Inhibitors and passive administration of a monoclonal anti-EGFR antibody, wherein the ALK Inhibitor is administered according to a continuous regimen based on an average daily dose in the range of 10 to 250 mg and the passive immunization is co-administered according to a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly, wherein the method results in preventing acquiring resistance to ALK Inhibitor treatment.

A method of treating a patient suffering from a non-small cell lung cancer (NSCLC) driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR) wherein the patient has a tumor expressing the ELM4-ALK fusion gene mutated, comprising administering to a patient in need of such treatment a flexible and active regimen for combining ALK Inhibitors and passive administration of a monoclonal anti-EGFR antibody, wherein in this method the ALK Inhibitor is administered according to a continuous regimen based on an average daily dose in the range of about 10 to 250 mg and the passive immunization is co-administered according to a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly, wherein the administration of ALK Inhibitors and said monoclonal anti-EGFR antibodies are administered thereafter.

A method of treating a patient suffering from a non-small cell lung cancer (NSCLC) driven by deregulated Human Epidermal Growth Factor Receptor (HER1/Human EGFR) NSCLC expressing the ELM4-ALK fusion gene, wherein:

• the patient has a tumor expressing mutated forms of the EGFR, comprising administering to a patient in need of such treatment a flexible and active regimen for combining an ALK Inhibitors and active immunization targeting EGF, wherein the active immunization is administered according to a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly, prior to the administration of a ALK Inhibitors in a continuous regimen based on an average daily dose in the range of about 10 to 250 mg and wherein the method results in preventing acquiring resistance to ALK Inhibitor treatment.